HCSGD entry for XRCC1
1. General information
| Official gene symbol | XRCC1 |
|---|---|
| Entrez ID | 7515 |
| Gene full name | X-ray repair complementing defective repair in Chinese hamster cells 1 |
| Other gene symbols | RCC |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
This gene isn't in PPI subnetwork.
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0000012 | Single strand break repair | IEA | biological_process |
| GO:0001666 | Response to hypoxia | IEA | biological_process |
| GO:0003684 | Damaged DNA binding | IEA | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005634 | Nucleus | IDA IEA | cellular_component |
| GO:0005654 | Nucleoplasm | TAS | cellular_component |
| GO:0006281 | DNA repair | TAS | biological_process |
| GO:0006284 | Base-excision repair | TAS | biological_process |
| GO:0010033 | Response to organic substance | IEA | biological_process |
| GO:0021766 | Hippocampus development | IEA | biological_process |
| GO:0042493 | Response to drug | IEA | biological_process |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.6161178489 | 0.1551710307 | 0.9999902473 | 0.7615619429 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | Up | 0.0511356800 |
| GSE13712_SHEAR | Down | -0.3464868910 |
| GSE13712_STATIC | Down | -0.4712098631 |
| GSE19018 | Down | -0.0809460445 |
| GSE19899_A1 | Down | -0.0845907428 |
| GSE19899_A2 | Up | 0.1362456811 |
| PubMed_21979375_A1 | Down | -0.0145478497 |
| PubMed_21979375_A2 | Up | 0.6260899649 |
| GSE35957 | Down | -1.0461246051 |
| GSE36640 | Down | -1.2117177924 |
| GSE54402 | Up | 0.4741597299 |
| GSE9593 | Down | -0.5574082143 |
| GSE43922 | Up | 0.0359487933 |
| GSE24585 | Up | 0.3483671483 |
| GSE37065 | Up | 0.3093520139 |
| GSE28863_A1 | - | - |
| GSE28863_A2 | - | - |
| GSE28863_A3 | - | - |
| GSE28863_A4 | - | - |
| GSE48662 | Down | -0.1271658656 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Not regulated by compounds
- Drugs
Not regulated by drugs
- MicroRNAs
- mirTarBase
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-miR-34a-5p | MIMAT0000255 | MIRT025546 | Proteomics | Functional MTI (Weak) | 21566225 |
| hsa-miR-92b-3p | MIMAT0003218 | MIRT040679 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-193b-3p | MIMAT0002819 | MIRT041371 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-186-5p | MIMAT0000456 | MIRT045144 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
No target information from mirRecord
- mirRecord
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 6 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 26474283 | Tyrosine kinase inhibitors (TKIs) including axitinib have been introduced in the treatment of renal cell carcinoma (RCC) because of their anti-angiogenic properties |
| 26474283 | However, no evidence are presently available on a direct cytotoxic anti-tumor activity of axitinib in RCC |
| 23744542 | Biallelic mutations of the von Hippel-Lindau (VHL) gene are the most common cause of sporadic and inherited renal cell carcinoma (RCC) |
| 23744542 | Cox regression analysis shows significant prediction of E2F1 expression for disease-free survival and overall survival, implying that E2F1 expression in kidney tumour is a novel prognostic factor for patients with RCC |
| 23578198 | Although multitargeted tyrosine kinase inhibitor sunitinib has been used as first-line therapeutic agent against metastatic renal cell carcinoma (mRCC), the molecular mechanism and functional role per se for its therapeutic performance remains obscure |
| 23578198 | Immunohistochemistry analysis of tumor tissues from RCC patients receiving sunitinib neoadjuvant therapy confirmed the similar treating phenotype |
| 22341977 | In this study, we investigated reptin expression in renal cell carcinoma (RCC) and its biologic functions in RCC cells |
| 22341977 | MATERIALS AND METHODS: A total of 81 RCC patients were involved in the study |
| 22341977 | Cytoplasmic expression of reptin positively correlates with the poor differentiation of RCC, and predicts an unfavorable outcome for patients |
| 22341977 | CONCLUSIONS: Reptin is overexpressed and aberrantly distributed in RCC |
| 22341977 | Furthermore, reptin promotes cell migration and invasion, which may contribute to the progression of RCC |
| 8828903 | We analyzed Southern blots of HINF1-digested DNA of a large number of renal cell carcinomas (RCC) including different tumor areas, secondary tumors and metastases (76 cases with 142 tumor samples) for changes in the length of telomeric repeats using the oligonucleotide probe (TTAGGG)3 and found telomere shortening in 54%, suggesting that a reduction of the telomeric repeat length is not a general characteristic in RCC |
| 8828903 | Shortened telomeres do not seem to be associated with advanced stages of tumor development or specific histopathological subtypes of RCC |
| 7493906 | Deletion of a gene(s) on chromosome 3 is common in human renal cell carcinoma (RCC) and reintroduction of a normal chromosome 3 into an RCC immortal cell line restored the program of cellular senescence |
Entries Per Page
Displaying Page of
